- Trials with a EudraCT protocol (53)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
53 result(s) found for: Coronary occlusion.
Displaying page 1 of 3.
EudraCT Number: 2013-000915-26 | Sponsor Protocol Number: CMMo-OCC-2012 | Start Date*: 2013-09-17 | |||||||||||
Sponsor Name:FUNDACIÓN PROGRESO Y SALUD | |||||||||||||
Full Title: Clinical Trial Phase III single-center, open-label efficacy of intracoronary infusion of bone marrow mononuclear cells in patients with occlusion Autologous chronic coronary revascularization and v... | |||||||||||||
Medical condition: Chronic coronary occlusion | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Temporarily Halted) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002675-17 | Sponsor Protocol Number: TIGER-BVS | Start Date*: 2014-05-30 |
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | ||
Full Title: Ticagrelor and absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization | ||
Medical condition: Chronic total coronary occlusion | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004392-23 | Sponsor Protocol Number: T189/2016 | Start Date*: 2018-02-08 |
Sponsor Name:Turku University Hospital | ||
Full Title: 68Ga-NODAGA-RGD cardiac PET in patients with acute myocardial infarction or chronic total coronary occlusion | ||
Medical condition: Acute or chronic coronary artery occlusion | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-002288-32 | Sponsor Protocol Number: ESR-14-10310 | Start Date*: 2016-11-14 | |||||||||||
Sponsor Name:Greek Corporation of Invasive Cardiology | |||||||||||||
Full Title: Ticagrelor Potentiation of Remote Ischemic Preconditioning: The Ticagrelor in Remote Ischemic Preconditioning (TRIP) study | |||||||||||||
Medical condition: Patient with NSTE-ACS referred for coronary angiography | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002343-30 | Sponsor Protocol Number: NEWTON-CABG | Start Date*: 2021-09-21 | |||||||||||
Sponsor Name:Unity Health Toronto, at its St. Michael’s site | |||||||||||||
Full Title: A randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery (NEWTON-CABG) | |||||||||||||
Medical condition: Patency of graft after coronary bypass graft surgery in patients with hyprelipidaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001452-42 | Sponsor Protocol Number: HCB.2021.1309 | Start Date*: 2023-01-12 |
Sponsor Name:HOSPITAL CLINIC BARCELONA | ||
Full Title: EVALUATION OF PATIENTS WITH TOTAL CORONARY OCCLUSIONS WITH MULTIMODALITY IMAGE | ||
Medical condition: Coronary artery chronic total occlusion | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002483-11 | Sponsor Protocol Number: 18HH4626 | Start Date*: 2019-05-15 | ||||||||||||||||
Sponsor Name:Imperial College London | ||||||||||||||||||
Full Title: CHOlesterol Reduction with Evolocumab and coronAry microvascuLar function: The CHORAL Flow Study | ||||||||||||||||||
Medical condition: Coronary artery disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007142-36 | Sponsor Protocol Number: CHPAU 2007/01 | Start Date*: 2008-05-07 | |||||||||||||||||||||
Sponsor Name:CH Pau | |||||||||||||||||||||||
Full Title: Evaluation des traitements anticoagulants lors d'angioplasties coronaires transcutanées non urgentes. | |||||||||||||||||||||||
Medical condition: Maladie coronaire athéromateuse nécessitant la réalisation d'une angioplastie coronaire transcutanée non urgente. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002142-50 | Sponsor Protocol Number: POPCABG03 | Start Date*: 2019-04-09 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery. | ||
Medical condition: Coronary artery bypass grafting surgery with the use of one or more saphenous vein grafts. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005575-96 | Sponsor Protocol Number: LPL100601 | Start Date*: 2008-11-26 |
Sponsor Name:GlaxoSmithKline Research & Development, Ltd | ||
Full Title: A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) | ||
Medical condition: chronic Coronary Heart Disease (cCHD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) ES (Completed) HU (Completed) SE (Completed) DE (Completed) GB (Completed) SK (Completed) FR (Completed) DK (Completed) EE (Completed) BE (Completed) CZ (Completed) PL (Completed) BG (Completed) IT (Completed) GR (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000238-16 | Sponsor Protocol Number: APD791-202 | Start Date*: 2021-05-07 | |||||||||||
Sponsor Name:Arena Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Effect on Microvascular Obstruction of Temanogrel in Subjects Undergoing Percutane... | |||||||||||||
Medical condition: Microvascular Obstruction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004825-14 | Sponsor Protocol Number: D1680C00016 | Start Date*: 2016-05-04 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A 24-Week, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Effects of Saxagliptin, Saxagliptin Combined with Dapagliflozin, and Sitagliptin in Pat... | |||||||||||||
Medical condition: Patients with type 2 diabetes mellitus and heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) HU (Completed) BG (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004649-28 | Sponsor Protocol Number: CTO-201 | Start Date*: 2015-10-09 |
Sponsor Name:Matrizyme Pharma Corporation | ||
Full Title: A 2-stage study to evaluate single doses of MZ-004 at different dose levels in patients with chronic total occlusions. STAGE 1: Open label Training Stage. STAGE 2: Double-blind, randomized, Pla... | ||
Medical condition: The use of MZ-004 to facilitate percutaneous coronary intervention in symptomatic patients with a chronic total occlusion who are indicated for revascularization | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003638-17 | Sponsor Protocol Number: HEMOPURE II and/or COR-002 | Start Date*: 2005-10-28 |
Sponsor Name:Biopure Corporation | ||
Full Title: This is a phase II, open-label study in the catheterization laboratory setting to challenge the concept that HBOC-201 ® administration might improve myocardial ‘oxygenation’ and myocardial function... | ||
Medical condition: Treatment of several ischemic conditions, such as acute coronary syndromes (ACS) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005491-27 | Sponsor Protocol Number: U-08-002 | Start Date*: 2008-11-26 | |||||||||||
Sponsor Name:UCR Uppsala Clinical Research Center | |||||||||||||
Full Title: TAILORING OF PLATELET INHIBITION TO AVOID STENT THROMBOSIS TOPAS-1 A Pharmacodynamic Phase II Study of Clopidogrel P2Y12 Platelet Inhibition | |||||||||||||
Medical condition: Previous patients in the TABR study treated with Plavix 75 mg/day and patients with stent thrombosis within 6 months or myocardial infarction within 6 month after stenting. For the control group no... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020497-41 | Sponsor Protocol Number: ANG.AMI-IC001 | Start Date*: 2013-02-13 | |||||||||||
Sponsor Name:Mesoblast, Inc. | |||||||||||||
Full Title: A prospective, double blind, randomized, placebo-controlled clinical trial of intracoronary infusion of immunoselected, bone marrow-derived Stro3 mesenchymal precursor cells (MPC) in the treatment ... | |||||||||||||
Medical condition: ST-elevation myocardial infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) DK (Completed) SE (Completed) CZ (Completed) AT (Prematurely Ended) PL (Completed) IT (Prematurely Ended) ES (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002876-26 | Sponsor Protocol Number: 2017-002876-26 | Start Date*: 2018-10-19 | |||||||||||
Sponsor Name:South Tees Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Telomerase ACTivator to reverse Immunosenescence in Acute Coronary Syndrome: a double-blind, phase II, pilot randomised controlled trial (TACTIC) | |||||||||||||
Medical condition: Immunosenescence in patients who have had an acute coronary syndrome diagnosed within the last 6 months. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002518-11 | Sponsor Protocol Number: 8835-004 | Start Date*: 2014-01-16 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES ME... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) NL (Completed) GB (Completed) IT (Completed) ES (Completed) BG (Completed) PL (Completed) GR (Completed) HR (Completed) SK (Completed) LT (Completed) LV (Completed) CZ (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001824-32 | Sponsor Protocol Number: 116174 | Start Date*: 2015-03-05 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in pa... | |||||||||||||
Medical condition: Diabetes mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) CZ (Completed) GB (Completed) SE (Completed) NL (Completed) HU (Completed) BE (Completed) DK (Completed) ES (Completed) BG (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004901-27 | Sponsor Protocol Number: HA007 | Start Date*: 2006-05-24 |
Sponsor Name:Nuvelo | ||
Full Title: A Phase 3, Multicenter, Multi-national, Randomized, Double-Blind, Placebo-Controlled study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects with Acute Peripheral Arterial Occlusion (N... | ||
Medical condition: Acute Peripheral Arterial Occlusion (acute PAO) is to peripheral vascular disease what acute coronary syndromes are to atherosclerotic heart disease and what stroke is to atherosclerotic cerebrovas... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) FI (Prematurely Ended) DK (Completed) HU (Completed) NL (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
